Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.070
-0.250 (-10.78%)
At close: Nov 4, 2024, 4:00 PM
2.100
+0.030 (1.45%)
After-hours: Nov 4, 2024, 5:11 PM EST

Company Description

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.

Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

The company’s lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.

It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer’s Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.

The company was founded in 2017 and is headquartered in Bethesda, Maryland.

Gain Therapeutics, Inc.
Gain Therapeutics logo
Country United States
Founded 2017
IPO Date Mar 18, 2021
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Gene Mack

Contact Details

Address:
4800 Montgomery Lane, Suite 220
Bethesda, Maryland 20814
United States
Phone 301 500 1556
Website gaintherapeutics.com

Stock Details

Ticker Symbol GANX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $11.00
CIK Code 0001819411
CUSIP Number 36269B105
ISIN Number US36269B1052
Employer ID 85-1726310
SIC Code 2834

Key Executives

Name Position
Gene Mack M.B.A. Chief Financial Officer and Interim Chief Executive Officer
Dr. Khalid Islam Ph.D. Executive Chairman
Dr. Joanne Taylor Ph.D. Senior Vice President of Research
Dr. Terenzio Ignoni Pharm.D. Senior Vice President of Technical Operations
Dr. Jonas Hannestad M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 21, 2024 8-K Current Report
Oct 8, 2024 8-K Current Report
Sep 19, 2024 S-8 Securities to be offered to employees in employee benefit plans
Sep 6, 2024 424B5 Filing
Sep 6, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 12, 2024 8-K Current Report
Jul 9, 2024 8-K Current Report
Jul 1, 2024 FWP Free Writing Prospectus